Literature DB >> 11515790

Glioblastoma-related gene mutations and over-expression of functional epidermal growth factor receptors in SKMG-3 glioma cells.

C Thomas1, G Ely, C D James, R Jenkins, M Kastan, A Jedlicka, P Burger, R Wharen.   

Abstract

Amplification of the epidermal growth factor receptor (EGFR) gene is found in about 40% of glioblastomas (GBMs) but is rarely detected in GBM cell lines. We confirmed that the exceptional SKMG-3 GBM cell line retained amplified EGFR genes in vitro, and found that these sequences were concentrated on extra-chromosomal DNA particles similar to double-minute chromosomes. The cells contained two other gene mutations that are associated with high-grade astrocytic tumors: extra-chromosomal amplification of the cyclin-dependent kinase-4 (CDK4) gene and a homozygous mutation within the PTEN tumor suppressor gene. Immunoblots revealed very high levels of EGFR, moderately increased expression of CDK4, and no detectable PTEN protein. The overexpressed SKMG-3 EGFRs responded to exogenous ligand and resembled normal rather than mutant receptors. A heterozygous mutation of the p53 gene (p53R282W) correlated with failure of radiation to induce the expression of cyclin-dependent kinase inhibitor p21waf1 or an early G1 cell cycle arrest. Although each of these gene mutations occurs in GBMs, SKMG-3 cells had an unusual genotype in that a p53 gene mutation co-existed with amplified EGFR genes. Nonetheless, the SKMG-3 cell line can be exploited as a model to study how oncogenic EGFR signals in GBM cells interact with over-expressed CDK4 and loss of PTEN to confer the malignant phenotype.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11515790     DOI: 10.1007/s004010000332

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  12 in total

Review 1.  RNA interference and nonviral targeted gene therapy of experimental brain cancer.

Authors:  Ruben J Boado
Journal:  NeuroRx       Date:  2005-01

2.  Effect and mechanism of epidermal growth factor on proliferation of GL15 gliomas cell line.

Authors:  Heping Wang; Dongsheng Guo; Fei Ye; Guifa Xi; Baofeng Wang; Jian Chen; Ting Lei
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

3.  Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.

Authors:  Caterina Giannini; Jann N Sarkaria; Atsushi Saito; Joon H Uhm; Evanthia Galanis; Brett L Carlson; Mark A Schroeder; C David James
Journal:  Neuro Oncol       Date:  2005-04       Impact factor: 12.300

Review 4.  Current state of our knowledge on brain tumor epidemiology.

Authors:  Quinn T Ostrom; Jill S Barnholtz-Sloan
Journal:  Curr Neurol Neurosci Rep       Date:  2011-06       Impact factor: 5.081

5.  The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells.

Authors:  Qing-Bai She; David B Solit; Qing Ye; Kathryn E O'Reilly; Jose Lobo; Neal Rosen
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

6.  Murine cell line model of proneural glioma for evaluation of anti-tumor therapies.

Authors:  Adam M Sonabend; Jonathan Yun; Liang Lei; Richard Leung; Craig Soderquist; Celina Crisman; Brian J Gill; Arthur Carminucci; Julia Sisti; Mike Castelli; Peter A Sims; Jeffrey N Bruce; Peter Canoll
Journal:  J Neurooncol       Date:  2013-03-16       Impact factor: 4.130

7.  Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics.

Authors:  Judith Jeuken; Angelique Sijben; Cristina Alenda; Jos Rijntjes; Marieke Dekkers; Sandra Boots-Sprenger; Roger McLendon; Pieter Wesseling
Journal:  Brain Pathol       Date:  2009-10       Impact factor: 6.508

8.  EGFR inhibition in glioma cells modulates Rho signaling to inhibit cell motility and invasion and cooperates with temozolomide to reduce cell growth.

Authors:  Guillem Ramis; Elena Thomàs-Moyà; Silvia Fernández de Mattos; José Rodríguez; Priam Villalonga
Journal:  PLoS One       Date:  2012-06-06       Impact factor: 3.240

9.  Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR.

Authors:  Jinsong Li; Huayun Deng; Meichun Hu; Yuanzhang Fang; Amanda Vaughn; Xiaopan Cai; Leqin Xu; Wei Wan; Zhenxi Li; Shijie Chen; Xinghai Yang; Song Wu; Jianru Xiao
Journal:  Oncotarget       Date:  2015-03-30

10.  Tumor versus stromal cells in culture--survival of the fittest?

Authors:  Krishna M Talasila; Narve Brekka; Kjersti Mangseth; Daniel Stieber; Lasse Evensen; Gro V Rosland; Anja Torsvik; Marek Wagner; Simone P Niclou; Rupavathana Mahesparan; Olav K Vintermyr; Rolf Bjerkvig; Janice M Nigro; Hrvoje Miletic
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.